Aripiprazole Tablet
Product Images NDC 50090-7564

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50090-7564). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Aripiprazole Fig1)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole,' showing fold changes and 90% confidence intervals in aripiprazole AUC and Cmax relative to reference without interacting drugs. The chart compares inhibitors, inducers, gastric acid blockers, and others affecting aripiprazole levels.*

FDA Label Image

Figure (Aripiprazole Fig2)

A chart titled 'Effect of Other Drugs on Aripiprazole' showing fold change and 90% confidence intervals for dehydro-aripiprazole pharmacokinetics (AUC and Cmax) when coadministered with various CYP3A4 and CYP2D6 inhibitors, inducers, gastric acid blockers, and other drugs. The x-axis represents change relative to reference without interacting drug, ranging approximately 0.0 to 3.0.*

FDA Label Image

Figure (Aripiprazole Fig3)

A scatter plot chart showing the effect of Aripiprazole on the pharmacokinetics (PK) of various drugs, including dextromethorphan, warfarin (S- and R- enantiomers), omeprazole, lamotrigine, valproate, lorazepam, venlafaxine, and O-desmethylvenlafaxine. The x-axis represents the fold change relative to a reference without interacting drug, and the y-axis lists the drugs with associated metabolic enzymes. Data points with 90% confidence intervals depict fold change values for different pharmacokinetic parameters such as DM/DR, AUC, Cmax, and INR.*

FDA Label Image

Figure (Aripiprazole Fig4)

A chart depicting Aripiprazole fold change with 90% confidence intervals across special populations. It compares pharmacokinetic parameters such as AUC and Cmax between different groups including CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and severe renal impairment, showing relative changes versus reference values.*

FDA Label Image

Figure (Aripiprazole Fig5)

A pharmacokinetic chart showing fold changes and 90% confidence intervals for Aripiprazole comparing variables such as CYP2D6 metabolism, gender, age, hepatic impairment, and severe renal impairment. The x-axis represents the change relative to reference for AUC and Cmax parameters.*

FDA Label Image

Figure 6: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (schizophrenia Study 5) (Aripiprazole Fig6)

Kaplan-Meier curve showing the cumulative proportion of patients with relapse over 182 days, comparing Aripiprazole and placebo groups in a schizophrenia study. The graph plots relapse proportion on the y-axis against days from randomization on the x-axis, with subject counts at risk indicated below.*

FDA Label Image

Figure 9: Least Square Means Of Change From Baseline In Ygtss Tts By Week (tourette’s Disorder Study 1) (Aripiprazole Fig7)

A line graph depicting the change in YGTSS total TIC score from baseline over 8 weeks of treatment. It compares three groups: Aripiprazole low dose, Aripiprazole high dose, and placebo. The y-axis shows least-squares mean change in YGTSS total TIC score, and the x-axis shows weeks of treatment. Both Aripiprazole groups show a greater reduction in scores over time compared to placebo.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Str)

Chemical structure of Aripiprazole, depicting the arrangement of atoms including chlorine-substituted aromatic rings, a piperazine ring, and other connected moieties characteristic of its molecular composition.*

FDA Label Image

Label Image (Lbl500907564)

Label for Aripiprazole 2 mg oral tablets from A-S Medication Solutions. The label includes the product NDC 50090-7564-0, the lot and expiration date fields, storage instructions to keep between 68 to 77 degrees Fahrenheit, and indicates a package containing 30 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.